1Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myclodysplastic syndromes[J]. J Clin Oncol, 2007, 25(23) :3503- 3510.
2Bouscary D, de Ves J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastie syndromes[J]. Leukemia, 1997,11 (6) :839-845.
4Bellamy WT, Richter L, Siqani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastie syndromes [ J ]. Blood, 2001,97 (5) : 1427-1434.
5Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodyspiatic syndromes[J]. Blood, 2001,98 (4) :958-965.
3Fabian I, Shvartzmayer S, Fibach E. Induction of morphological and functional differentiation of human myeloid leukemia cells (HL-60 and LK) by a benzoic acid derivative of retinoic acid. Leuk Res,1987; 11:863- 868
4Hebbar M, Kaplan C, Caulier MT, et al. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to
5Shibakura M, Niiya K, Kiguchi T, et al. Simultaneous induction of matrix metalloproteinase-9 and interleukin 8 by all-trans retinoic acid in human PL-21 and NB4 myeloid leukaemia cells. Br J Haematol,2002; 118:419 - 425
6Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndrome. Br J Haemetol, 1991; 77:502 -508
7Chan GW, Divenuti G, miller K. Danazol for the treatment of thrombocytopenia in myelodysplastic Syndromes(abstract). Blood,2000; 96:147a
8Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effect in myelodysplastic syndrome. J Clin Oncol,1993; 11:1489- 1495
9Hast R, Beksac M, Axdorph S, et al. Effects of retinoids on in vitro differentiation of bone marrow cells in the myelodysplastic syndrome. Med Oncol Tumor Pharmacother, 1986; 3:35- 38
10Letendre L, Levitt R, Pierre RV, et al. Myelodysplasic syndrome treatment with danazol and cis-retinoic acid. Am J Hematol, 1995;48:233 - 236
4Huang ME,Ye YC ,Chen SR,et al. Use of all trans retinoic acid in the treatment of promyelocytic leukemia[ J]. Blood, 1988,72 ( 2 ) : 567-572.
5Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia[ J]. N Engl J Med, 1997,337 ( 15 ) : 1021-1028.
6Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0439 protocol for newly diagnosed acute promyelocytie leukemia: very long-term resuits and role of maintenance [ J]. Blood, 2011, 117 (18): 4716 -4725.
7Gianni M, KoKen MH, Chelbi-Alix MK, et al. Comdined arseni- eaeidand relinoieaeid treatment enhances differentiationandapop2 tosis in arsenic-resistan IVB4 cell[ J]. Blood, 1998,91 ( 11 ) :4300- 4310.
8Guo W, Wang H,Zhao W,et al. Effect of all-trans retino2 ieacidan- darsenie trioxideon tissuefaetor expression of acutepro 2 myelocytic leukemia[J]. Chin Med J(Engl) ,2001,114(1 ) :30-34.
9Kantarjian H, Issa JP, Rosenfeld CS, et al. Deeitabine improves patient outcomes in myelodysplastic syndromes:results of a phase randomized study [ J ]. C ancer,2006,106 ( 8 ) :1794-1803.
10Sekeres MA, List AF, Cuthbertson D,et al. phase I combina- tion trial of lenalidomide and azacitidine in patients with higher- risk myelodysplastic syndromes [ J ] J Clin Oneol, 2010,28 ( 18 ) : 2253 -2258.
